Special Focuses

1. Plan and Content of Service 

The core facility of TACC-P1 will provide participants molecular profiling service under a collaborative clinical research. TACC-P1 will provide 50 molecular profiling samples per year to cover the subjects entering oncology phase I clinical trials. Participating subjects need to sign the informed consent for tumor molecular profiling and circulating tumor cells/plasma/serum storage. Core clinical information will be collected for future analysis. We plan to collect 150 advanced solid tumor samples in 3 years. TACC-P1 and core laboratory also provide additional samples profiling capability for other collaborative studies proposed in other NRPB grant or other independent grant.

2. Anticipated Milestones and Timeline

We plan to collect 150 advanced solid tumor samples in 3 years.

3.  Anticipated Outcomes and Future Development

  1. To perform 15 industry-sponsored or investigator-initiated oncology phase I trials that can be conducted or led by Taiwan Investigators in 3 years.
  2. To collect and analyze annotated 150 tumor samples from oncology phase I trials’ participants using the Sequenom OncoCarta mutation platform in 3 years.
  3. To allocate oncology phase I trials’ participants to different oncology phase I trials based on the above molecular profiling (“educated” guess).